Genes may interact with obstetric complications to boost schizophrenia riskJanuary 15, 2008The cause of schizophrenia is thought to include both epistasis and gene-environment interactions. We sought to test whether a set of schizophrenia candidate genes regulated by hypoxia or involved in vascular function in the brain (AKT1, BDNF, CAPON, CHRNA7, COMT, DTNBP1, GAD1, GRM3, NOTCH4, NRG1, PRODH, RGS4, TNF-á) interacted with serious obstetric complications to influence risk for schizophrenia. A family-based study of transmission disequilibrium was conducted in 116 trios. Twenty-nine probands had at least one serious obstetric complication (OC) using the McNeil-Sjostrom Scale, and many of the OCs reported were associated with the potential for fetal hypoxia. Analyses were conducted using conditional logistic regression and a likelihood ratio test (LRT) between nested models was performed to assess significance. Of the 13 genes examined, 4 (AKT1 (3 SNPs), BDNF (2 SNPs), DTNBP1 (1 SNP) and GRM3 (1 SNP)) showed significant evidence for gene-by-environment interaction (LRT p-values ranged from 0.011-0.037). Although our sample size was modest and therefore the power to detect interactions was limited, we report significant evidence for genes involved in neurovascular function or regulated by hypoxia interacting with the presence of serious obstetric complications to increase risk for schizophrenia. Molecular Psychiatry | |||||||||||||||||||||
|
Related Schizophrenia News Articles Anti-psychotic drug use in the elderly increases despite drug safety warnings Three regulatory warnings of serious adverse events slowed the growth of use of atypical antipsychotic drugs among elderly patients with dementia, but they did not reduce the overall prescription rate of these drugs. Looking beyond the drug receptor for clues to drug effectiveness Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed. Severe, acute maternal stress linked to the development of schizophrenia Pregnant women who endure the psychological stress of being in a war zone are more likely to give birth to a child who develops schizophrenia. Unlocking mystery of why dopamine freezes Parkinson's patients Parkinson's disease and drug addiction are polar opposite diseases, but both depend upon dopamine in the brain. Parkinson's patients don't have enough of it; drug addicts get too much of it. Although the importance of dopamine in these disorders has been well known, the way it works has been a mystery. Human brains pay a price for being big Metabolic changes responsible for the evolution of our unique cognitive abilities indicate that the brain may have been pushed to the limit of its capabilities. Research published today in BioMed Central's open access journal Genome Biology adds weight to the theory that schizophrenia is a costly by-product of human brain evolution. Estrogen relieves psychotic symptoms in women with schizophrenia When combined with antipsychotic medications, the estrogen estradiol appears to be a useful treatment in women with schizophrenia, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals. N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction. Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time. Protein marker for schizophrenia risk A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics. Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals. More Schizophrenia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||